Literature DB >> 10329384

Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line.

Y Soda1, N Shimizu, A Jinno, H Y Liu, K Kanbe, T Kitamura, H Hoshino.   

Abstract

CD4 and one of the G-protein-coupled receptors (GPCRs) on the cell surface function as a receptor and a coreceptor, respectively, in infection of cells with human and simian immunodeficiency viruses (HIV/SIV). To determine which GPCRs can be coreceptors for HIV (HIV-1 and HIV-2) or SIV infection, several cell lines, including human osteosarcoma HOS-T4 cells and human glioma U87/CD4 cells, have been used. However, these cells often show susceptibilities to some HIV or SIV strains before transduction of GPCRs. The results of this study showed that a CD4-transduced human glioma cell line, NP-2/CD4, a human erythroleukemia cell line, K562/CD4, and a human ovarian cancer cell line, TYK/CD4, were completely resistant to the HIV-1 and HIV-2 strains tested. After transduction of several GPCRs into NP-2/CD4, K562/CD4, or TYK/CD4 cells, NP-2/CD4 cells but not K562/CD4 or TYK/CD4 cells mostly showed expected susceptibilities to several HIV strains. Therefore, an NP-2 cell system would be useful to determine the coreceptor usage of HIV isolates, to find a new coreceptor for HIV/SIV, and to analyze the early stages of HIV/SIV infection. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10329384     DOI: 10.1006/bbrc.1999.0633

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  54 in total

1.  Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C.

Authors:  Mia Coetzer; Rebecca Nedellec; Tonie Cilliers; Tammy Meyers; Lynn Morris; Donald E Mosier
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

2.  Repression of the HIV-1 5' LTR promoter and inhibition of HIV-1 replication by using engineered zinc-finger transcription factors.

Authors:  Lindsey Reynolds; Christopher Ullman; Michael Moore; Mark Isalan; Michelle J West; Paul Clapham; Aaron Klug; Yen Choo
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

3.  Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Authors:  Kieran Cashin; Michael Roche; Jasminka Sterjovski; Anne Ellett; Lachlan R Gray; Anthony L Cunningham; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

4.  Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Rebecca Nedellec; Alejandra Ramos; Oliver Hartley; John L Miamidian; Jacqueline D Reeves; Donald E Mosier
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

5.  Distinct requirements for HIV-cell fusion and HIV-mediated cell-cell fusion.

Authors:  Naoyuki Kondo; Mariana Marin; Jeong Hwa Kim; Tanay M Desai; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2015-01-14       Impact factor: 5.157

6.  Existence of Replication-Competent Minor Variants with Different Coreceptor Usage in Plasma from HIV-1-Infected Individuals.

Authors:  Yosuke Maeda; Taichiro Takemura; Takayuki Chikata; Takeo Kuwata; Hiromi Terasawa; Riito Fujimoto; Nozomi Kuse; Tomohiro Akahoshi; Hayato Murakoshi; Giang Van Tran; Yu Zhang; Chau Ha Pham; Anh Hong Quynh Pham; Kazuaki Monde; Tomohiro Sawa; Shuzo Matsushita; Trung Vu Nguyen; Kinh Van Nguyen; Futoshi Hasebe; Tetsu Yamashiro; Masafumi Takiguchi
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

7.  CXCR4-tropic, but not CCR5-tropic, human immunodeficiency virus infection is inhibited by the lipid raft-associated factors, acyclic retinoid analogs, and cholera toxin B subunit.

Authors:  Haruka Kamiyama; Katsura Kakoki; Sayuri Shigematsu; Mai Izumida; Yuka Yashima; Yuetsu Tanaka; Hideki Hayashi; Toshifumi Matsuyama; Hironori Sato; Naoki Yamamoto; Tetsuro Sano; Yoshihiro Shidoji; Yoshinao Kubo
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-27       Impact factor: 2.205

8.  Interferon-alpha mediates restriction of human immunodeficiency virus type-1 replication in primary human macrophages at an early stage of replication.

Authors:  Kelly M Cheney; Áine McKnight
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

9.  Isolation and characterization of a replication-competent molecular clone of an HIV-1 circulating recombinant form (CRF33_01B).

Authors:  Kok Keng Tee; Shigeru Kusagawa; Xiao-Jie Li; Narumi Onogi; Maya Isogai; Saiki Hase; Rie Uenishi; Huanan Liao; Adeeba Kamarulzaman; Yutaka Takebe
Journal:  PLoS One       Date:  2009-08-18       Impact factor: 3.240

10.  A robust lentiviral pseudotype neutralisation assay for in-field serosurveillance of rabies and lyssaviruses in Africa.

Authors:  Edward Wright; Suzanne McNabb; Trudy Goddard; Daniel L Horton; Tiziana Lembo; Louis H Nel; Robin A Weiss; Sarah Cleaveland; Anthony R Fooks
Journal:  Vaccine       Date:  2009-11-27       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.